Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and the effect of transarterial chemoembolization
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF RADIOLOGY
- Issue:
- 12
- DOI:
- 10.3760/j.issn:1005-1201.2003.12.005
- Key Word:
- 癌,肝细胞;血管生成因子;化学栓塞,治疗性;酶联免疫吸附测定
Abstract： 目的研究血管内皮生长因子(vascular endothelial growth factor, VEGF)在肝细胞癌(hepatocellular carcinoma, HCC)患者血浆中的表达水平与肝癌临床病理特征间的关系及其在动脉化疗栓塞(transarterial chemoembolization, TACE)治疗前后的变化.方法 45例临床诊断为HCC的患者,于TACE术前、术后1、3、7 d及1个月抽血,用酶联免疫吸附测定法(ELISA法)定量检测血浆中VEGF水平,同时对20例肝脏良性疾病患者及17 例健康人血浆中VEGF水平进行检测.结果 HCC组血浆VEGF表达水平明显高于肝脏良性疾病组(P=0.006)及健康对照组(P=0.003).血浆VEGF表达水平随HCC患者TNM分级的升高而逐步升高(P=0.044),较高血浆VEGF表达见于肿瘤较大(P=0.006),以及并发有门脉癌栓(P=0.011)、远处转移(P=0.017)或动-门脉瘘(P=0.026)的病人.血浆VEGF的水平与血小板水平弱相关(r=0.312, P=0.038),与血清甲胎蛋白(AFP)水平不相关(r=0.068, P=0.658).TACE术后1 d血浆VEGF水平明显升高,与术前相比差异有显著性意义;其后3、7 d逐渐下降,与术前相比差异无显著性意义.血浆VEGF变化率(术后1个月/术前×100%)与患者碘油积聚(rs=0.494, P=0.001)及病灶变化情况(rs=0.340, P=0.034)相关.术前血浆VEGF水平较高患者对TACE治疗反应较差(P=0.018).结论在临床、影像学及AFP检查的基础上,通过动态检测血浆VEGF能更好地反映肿瘤的临床病理特征,有望在肝癌诊断、转移复发潜能判断,以及TACE疗效预判、疾病进程监测、治疗方案选择等方面发挥重要作用.
- [1]刘佩芳,鲍润贤,牛昀,等.乳腺良恶性病变动态增强MRI表现特征与血管生成相关性的初步研究[J].2002,(11).
- [2]李欣,冯敢生,郑传胜,等.肝动脉化疗栓塞对肿瘤血管生成影响的实验研究[J].2002,(8).
- [3]H, Suzuki,M, Mori,C, Kawaguchi,etc.Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.[J].1999,14.
- [4]S, Kondo,M, Asano,K, Matsuo,etc.Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.[J].1994,1221.
- [5]Fuyuhiko Akiyoshi,Michio Sata,Hiroshi Suzuki,etc.Serum Vascular Endothelial Growth Factor Levels in Various Liver Diseases[J].1998,43(1).
- [6]P, Salven,T, Ruotsalainen,K, Mattson,etc.High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.[J].1998,79.
- [7]Nasu R,Akagi K,Kimura H,etc.Blood flow influences vascular growth during tumour angiogenesis.[J].1999,79(5).
- [8]I Hyodo,T Doi,H Endo,etc.Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer[J].1998,34(13).
- [9]Verheul HM,Pinedo HM,Folkman J,etc.Involvement of platelets in tumour angiogenesis?[J].1998,352(9142).
- [10]Fabien N,Bienvenu JA,Gutowski MC,etc.Cytokine assays in human sera and tissues.[J].1998,129(1).
- [11]P, Salven,L, Teerenhovi,H, Joensuu.A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.[J].1997,90.
- [12]H, Shimada,A, Takeda,Y, Nabeya,etc.Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.[J].2001,92(3).
- [13]Robert Mohle,David Green,Malcolm A. S. Moore.Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets[J].1997,94(2).
- [14]Lee JK,Han CJ,Hwang DY,etc.Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?[J].2000,17(1).
- [15]H M, Verheul,K, Hoekman,S, Luykx-de Bakker,etc.Platelet: transporter of vascular endothelial growth factor.[J].1997,3.